Zacks Research Has Optimistic Outlook of Bruker Q4 Earnings

Bruker Co. (NASDAQ:BRKR) – Research analysts at Zacks Research lifted their Q4 2025 earnings per share estimates for Bruker in a report issued on Wednesday, May 28th. Zacks Research analyst R. Department now expects that the medical research company will earn $0.91 per share for the quarter, up from their prior forecast of $0.88. The consensus estimate for Bruker’s current full-year earnings is $2.69 per share. Zacks Research also issued estimates for Bruker’s Q1 2026 earnings at $0.48 EPS, Q2 2026 earnings at $0.50 EPS, FY2026 earnings at $2.61 EPS, Q1 2027 earnings at $0.64 EPS and FY2027 earnings at $3.05 EPS.

Bruker (NASDAQ:BRKR) last announced its quarterly earnings results on Wednesday, May 7th. The medical research company reported $0.47 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.46 by $0.01. The firm had revenue of $801.40 million during the quarter, compared to the consensus estimate of $763.83 million. Bruker had a return on equity of 21.01% and a net margin of 3.36%. The firm’s quarterly revenue was up 11.0% compared to the same quarter last year. During the same period in the prior year, the company posted $0.53 earnings per share.

Other equities analysts also recently issued reports about the company. Guggenheim reaffirmed a “buy” rating on shares of Bruker in a report on Monday, February 24th. Citigroup downgraded Bruker from a “strong-buy” rating to a “hold” rating and decreased their price objective for the company from $50.00 to $40.00 in a report on Thursday, May 22nd. Stifel Nicolaus decreased their price objective on Bruker from $57.00 to $48.00 and set a “hold” rating for the company in a report on Thursday, May 8th. The Goldman Sachs Group decreased their price objective on Bruker from $50.00 to $45.00 and set a “neutral” rating for the company in a report on Thursday, May 8th. Finally, UBS Group decreased their price objective on Bruker from $57.00 to $45.00 and set a “neutral” rating for the company in a report on Thursday, May 8th. Six research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus target price of $59.10.

Bruker Stock Performance

Shares of BRKR opened at $36.63 on Friday. The stock has a 50 day moving average price of $38.62 and a 200 day moving average price of $49.01. The company has a quick ratio of 0.77, a current ratio of 1.60 and a debt-to-equity ratio of 1.15. The company has a market capitalization of $5.55 billion, a price-to-earnings ratio of 48.20, a price-to-earnings-growth ratio of 2.16 and a beta of 1.23. Bruker has a 52-week low of $34.10 and a 52-week high of $72.94.

Bruker Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, June 27th. Stockholders of record on Monday, June 16th will be given a $0.05 dividend. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.55%. The ex-dividend date is Monday, June 16th. Bruker’s dividend payout ratio is currently 38.46%.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. Pinnacle Bancorp Inc. purchased a new position in shares of Bruker in the first quarter valued at $29,000. Allworth Financial LP boosted its stake in shares of Bruker by 92.4% during the first quarter. Allworth Financial LP now owns 758 shares of the medical research company’s stock valued at $30,000 after acquiring an additional 364 shares during the last quarter. Caitong International Asset Management Co. Ltd boosted its stake in shares of Bruker by 1,354.5% during the first quarter. Caitong International Asset Management Co. Ltd now owns 800 shares of the medical research company’s stock valued at $33,000 after acquiring an additional 745 shares during the last quarter. Annis Gardner Whiting Capital Advisors LLC acquired a new stake in shares of Bruker during the first quarter valued at $42,000. Finally, MassMutual Private Wealth & Trust FSB boosted its stake in shares of Bruker by 274.9% during the first quarter. MassMutual Private Wealth & Trust FSB now owns 1,091 shares of the medical research company’s stock valued at $46,000 after acquiring an additional 800 shares during the last quarter. Hedge funds and other institutional investors own 79.52% of the company’s stock.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.